 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 90Y-besilesomab (TLX66) / Telix
Enrollment open, Trial completion date, Trial primary completion date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Oct 3, 2023
P2, N=25, Recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Sep 2025
- | 90Y-besilesomab (TLX66) / Telix
Trial primary completion date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - May 16, 2023
P2, N=25, Not yet recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Sep 2025 Trial primary completion date: Jun 2023 --> Oct 2023
- | 90Y-besilesomab (TLX66) / Telix
Trial initiation date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Mar 16, 2022
P2, N=25, Not yet recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Trial primary completion date: Jun 2023 --> Oct 2023 Initiation date: Jan 2022 --> Apr 2022
- | 90Y-besilesomab (TLX66) / Telix
Trial initiation date: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Dec 16, 2021
P2, N=25, Not yet recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Initiation date: Jan 2022 --> Apr 2022 Initiation date: Jun 2021 --> Jan 2022
- | 90Y-besilesomab (TLX66) / Telix
New P2 trial: RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - Apr 23, 2021
P2, N=25, Not yet recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
- | 90Y-besilesomab (TLX66) / Telix
Trial completion, Enrollment change: Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia (clinicaltrials.gov) - Oct 22, 2020
P1, N=9, Completed, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Initiation date: Jun 2021 --> Jan 2022 Recruiting --> Completed | N=24 --> 9
- | 90Y-besilesomab (TLX66) / Telix
Trial completion date, Trial primary completion date: Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia (clinicaltrials.gov) - May 4, 2020
P1, N=24, Recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Recruiting --> Completed | N=24 --> 9 Trial completion date: Nov 2019 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Jun 2020
- | 90Y-besilesomab (TLX66) / Telix
New P1 trial: Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia (clinicaltrials.gov) - Sep 9, 2019
P1, N=24, Recruiting, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust